Dysregulation of Gene Expression in a Lysosomal Storage Disease Varies between Brain Regions Implicating Unexpected Mechanisms of Neuropathology by Parente, Michael K. et al.
Dysregulation of Gene Expression in a Lysosomal
Storage Disease Varies between Brain Regions
Implicating Unexpected Mechanisms of Neuropathology
Michael K. Parente
1., Ramona Rozen
1.¤a, Cassia N. Cearley
1¤b, John H. Wolfe
1,2*
1Research Institute of the Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States of America, 2W.F. Goodman Center for Comparative Medical
Genetics, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
Abstract
The characteristic neurological feature of many neurogenetic diseases is intellectual disability. Although specific
neuropathological features have been described, the mechanisms by which specific gene defects lead to cognitive
impairment remain obscure. To gain insight into abnormal functions occurring secondary to a single gene defect, whole
transcriptome analysis was used to identify molecular and cellular pathways that are dysregulated in the brain in a mouse
model of a lysosomal storage disorder (LSD) (mucopolysaccharidosis [MPS] VII). We assayed multiple anatomical regions
separately, in a large cohort of normal and diseased mice, which greatly increased the number of significant changes that
could be detected compared to past studies in LSD models. We found that patterns of aberrant gene expression and
involvement of multiple molecular and cellular systems varied significantly between brain regions. A number of changes
revealed unexpected system and process alterations, such as up-regulation of the immune system with few inflammatory
changes (a significant difference from the closely related MPS IIIb model), down-regulation of major oligodendrocyte genes
even though white matter changes are not a feature histopathologically, and a plethora of developmental gene changes.
The involvement of multiple neural systems indicates that the mechanisms of neuropathology in this type of disease are
much broader than previously appreciated. In addition, the variation in gene dysregulation between brain regions indicates
that different neuropathologic mechanisms may predominate within different regions of a diseased brain caused by a single
gene mutation.
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Introduction
Intellectual disability is a prominent feature of many monogenic
diseases affecting the brain. However, the mechanisms by which
specific gene defects lead to cognitive impairment remain obscure.
Detailed understanding of the relationship of specific pathologic
changes to systems defects is lacking, especially since pathological
lesions are often present in many areas of the brain. Little data is
available on the effects of global disease on different sub-regions of
the brain. To gain insight into regional differences in abnormal
functions occurring secondary to a single gene defect, we used
whole transcriptome analysis to identify molecular and cellular
pathways that are dysregulated in the brain in a mouse model of a
lysosomal storage disorder (LSD).
The LSDs constitute a large group of neurogenetic diseases in
which un-degraded macromolecules accumulate in the lysosome.
Specific neuropathologic features occur in many LSDs, including
meganeurites, neurite sprouting, ectopic dendrites, and axonal
spheroids [1] [2]. Storage lesions are present throughout the brain,
but structural abnormalities can be concentrated in types of
neurons or specific regions; e.g. GABAergic neurons exhibit
neuroaxonal dystrophy more than other cell types [1] and
neurodegeneration can occur in selective regions involved in
cognition [3]. Like most neurodegenerative diseases, astrogliosis
and neuroinflammation are present in LSD brains [4]. Despite the
availability of many well-characterized animal models of LSDs,
understanding of the role of cellular and molecular changes in the
phenotype of the brain disease is at best incomplete [5,6].
We investigated the widely studied mouse model of mucopoly-
saccharidosis (MPS) VII, caused by deficiency of b-glucuronidase
(GUSB) [7]. Humans with MPS VII have a broad spectrum of
clinical signs including variable intellectual disability [8]. MPS VII
mice have widespread storage lesions in the CNS [9]. Gene
expression studies on the brain in this and other MPS and LSD
models have been limited, however, by using whole brain, large
pieces that included parts from multiple sub-regions, pooled
samples, small numbers of samples, single substructures, or
analysis of a limited number of genes.
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32419Our data show that patterns of aberrant gene expression due to
disease vary significantly between major brain sub-structures and
involve multiple neural pathways, demonstrating greater com-
plexity of abnormalities than seen previously. 1) Comparing MPS
VII to the closely related MPS IIIB (the most extensively studied
MPS model) showed a different pattern of inflammatory and
immune system activation, reflecting differences in the predom-
inant glycosaminoglycan substrate accumulated in each disease. 2)
There was substantial down-regulation of oligodendrocyte genes
even though white matter disease is not a feature by histopathol-
ogy. 3) Many developmental genes were altered even though the
brains were from adults with advanced disease. The involvement
of many important neural systems, and the variation in which
systems are dysregulated between regions, indicate that the
mechanisms of neuropathology in this type of disease are much
broader than previously appreciated.
Results
1. Variation between regions in normal mouse brain
Differences between the six regions in the normal mice were
analyzed by determining if the region with the maximum
expression was significantly above the mean of the other regions
at a p* of #0.01. The number of genes enriched relative to other
regions were: cerebral cortex (CT) 1383 genes (1668 probes);
hippocampus (HP) 2165 genes (2656 probes); olfactory bulb (OB)
1877 genes (2341 probes); brain stem (BS) 2923 genes (3718
probes); cerebellum (CB) 1178 genes (1418 probes); rest (largely
striatum and thalamus)(ST) 1613 genes (1852 probes). The most
highly expressed genes (defined as $20 fold change over the mean
of the other regions) are shown in a heat map (Figure 1). This list
was compared to 22 previously reported regional markers
[10,11,12,13,14,15]. Twenty (20) of these had the highest
expression in the same region in our cohort and the other 2 were
found in the region with the second highest level of expression.
2. General observations on MPS VII versus normal brains
The large cohort of control and diseased brains allowed analysis
of the gene expression changes at the p*#0.01 level. Since a tightly
regulated gene with a small proportional change in magnitude
may be biologically significant, a minimum fold change was not
used [16]. Overall there were 853 genes (970 probes) altered in at
least one region of the mutant mouse brain (Table 1) with the
largest number of changes in the olfactory bulb. A number of
genes showed significant changes in multiple regions (shared) but
the majority were changed only in one brain region (unshared)
(Table 2).
The significantly changed genes were analyzed using GeneTrail
(http://genetrail.bioinf.uni-sb.de) [17] for Gene Ontology (GO)
terms [18] and KEGG pathway enrichment [19], and then were
evaluated by DAVID (http://david.abcc.ncifcrf.gov/) for func-
tional clustering [20]. The GeneTrail results showed 712 GO-term
associations and enrichment of 10 KEGG pathways, with the most
significantly over-represented GO-terms shown in Table 3 (full
data at http://repository.upenn.edu/wfg_ccmg) and all of the
KEGG pathways shown in Table 4. The DAVID analysis showed
Figure 1. Regional variation of highest expressed genes in
normal mouse brain. The log 2 expression levels for genes with a
.20 fold increase in expression level over the mean of the other 5
regions were determined and grouped according to highest expressing
region. Color bar at bottom shows range of values. Specific genes are
listed in right hand column.
doi:10.1371/journal.pone.0032419.g001
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grouped into the following: apoptosis, cell cycle, cell migration,
circadian rhythm, development, extracellular matrix/adhesion,
immune and inflammatory, ion transport/channels, metabolism,
myelination, neural disease, neuron, neuropeptide/hormone,
nucleus/gene regulation, signaling, transporter, and ubiquitin.
Expression of the Gusb gene was significantly down-regulated in
all brain regions in the MPS VII mice (average p*=1.4610
27).
This was expected because the mutation is at the 39 end of the gene
andresultsina verylowleveloftranscriptionduetoinstabilityofthe
mutant mRNA [21]. Many other lysosomal genes were up-
regulated (Figure 2), which was also expected since secondary
elevation of enzymatic activities of other lysosomal enzymes is a
common feature in LSDs, including MPS VII [22,23,24]. The
reduced expression in Gusb and increased expression of Hexb were
confirmed by RT-PCR (Fig. S1). In addition to the genes that are
listed in the DAVID Lysosome cluster, 5 more recently identified
lysosomal genes were also up-regulated [25].
We also examined genes of the recently identified CLEAR
(Coordinated Lysosomal Expression and Regulation) network regu-
lated by transcription factor EB (TFEB) [26,27]. However, the changes
in the MPS VII brain were limited to several genes in the lysosomal-
hydrolases-and-accessory-proteins group and only one of the autoph-
agy target genes (HIF1A) was changed. None of the TFEB target genes
involving lysosomal membranes, acidification, or biogenesis were
changed. This suggests that the gene expression changes in a single
lysosomal enzyme deficiency state are either unrelated to the CLEAR
network or possibly involve other unknown regulatory factors.
3. Regional differences between normal and MPS VII
mouse brain
Many genes showed changes in various regional combinations.
A large number were changed in one region exclusively or lacked
change in one region exclusively (Table S2). The direction of
change was always the same across regions, with only one
exception (Enpp2), which had mixed up/down regulation. For the
changes that were found in only one region, the OB had the most
(239) followed by the BS (154), CB (96), CT (50), HP (33) and ST
(33). Examples are the 11-fold down-regulation in the OB of
olfactory marker protein (Omp), expressed specifically in olfactory
neurons, which when inactivated alters odorant perception
[14,28]; and the 8-fold down-regulation in the HP of Otx2 which
controls neuron subtype identity, the fate of GABAergic neurons,
and forebrain development [29,30,31]. There were 41 genes that
were changed in five of the six regions (unchanged in only one),
with the CB having 4 times as many of the unchanged genes as the
next closest region (BS). The CT, HP, and OB each had only a
single gene that was exclusively unchanged in each region.
There also were regional variations in the clusters of genes
related to specific pathology and functions (GO-term categories).
For example, the OB ranked highest in immune system process,
ensheathment of neurons, inflammatory response, and regulation
of action potential, while the CB was the only region with no
changes in ensheathment of neurons or action potential. The
GeneTrail analysis of each set of regionally unique gene changes
found enrichment of GO terms specific to each region. However,
most of the functional categories of the DAVID clusters were also
identified by the overall analysis, as shown below.
4. Gene expression changes underlying specific
neuropathologies
The Pathognomonic lesion in MPS VII and the other LSDs is
engorged lysosomes in cells [9]; and a number of neuronal
dysmorphologies are found in the brain [1]. A number of other
morphological, biochemical, and behavioral abnormalities have
been found in the MPS VII model and changes in gene expression
in specific pathways were found that implicate specific cellular
processes that underlie them.
4a. Neurodegeneration. The MPS VII mouse brain has
specific regional changes in neurodegeneration, which are
concentrated in the hippocampus, cerebral cortex and striatum [3].
The neurodegeneration is characterized by progressive accumulation
of ubiquitin and neurofilament and the absence of other neuro-
degeneration sub-types characterized by PHF-Tau, alpha-synuclein,
or apoptosis [3]. Abnormal levels of ubiquitin and neurofilament are
seen in some glia as well as neurons. However, the evaluation of brain
homogenatesbygenearraymeasuresgeneexpressionfromamixture
of neural cell types. To determine if alterations in the MPS VII brain
regions were associated with specific neural cell types, we compared
our results to a panel of genes that are highly expressed in specific
isolated populations of neurons, oligodendrocytes, or astrocytes in
vitro [32]. Despite the morphologic change in most neurons [9] only
3 out of 80 neuron-specific marker genes were altered: upregulation
of Asph in BS, and Cyb561 and Lpl in CB.
Among all the neuronal receptor genes represented in the array,
changes were seen in only 4 out of 121, and only in one region
each: 1) up-regulation in the BS of the gamma-aminobutyric acid
(GABA)-A receptor subunit alpha 6 (Gabra6); 2) down-regulation
in the CT of the adrenergic receptor Adra1b; 3) down-regulation
in the CT of the class III glutamate receptor, Grm8; and 4) up-
regulation in the BS of Slc1a6, the high affinity glutamate
transporter (Table S3). There could, though, be significant
changes in individual neurons or small nuclei that would not
appear against the background of the regional homogenates.
The gene expression arrays scored very high in the order of
cluster-related GO-terms for genes associated with apoptosis. In
contrast, histopathological analysis shows no evidence for
increased apoptosis in the MPS VII mouse brain [3]. Although
Table 1. Regional gene changes in MPS VII.
Region Number of genes (probes) altered
Cortex (CT) 236 (271)
Hippocampus (HP) 180 (214)
Olfactory bulb (OB) 454 (515)
Brain stem (BS) 302 (342)
Cerebellum (CB) 191 (213)
Striatum/Thalmus (ST) 191 (214)
doi:10.1371/journal.pone.0032419.t001
Table 2. Number of gene expression changes shared by
different regions.
Number of shared regions Number of genes
All 6 38
54 1
44 0
36 2
21 3 9
unshared (single region) 591
doi:10.1371/journal.pone.0032419.t002
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Gene Ontology expected observed p-value(fdr)
lytic vacuole 7.46 40 6.36E-16
lysosome 7.46 40 6.36E-16
immune system process 35.00 91 1.48E-14
vacuole 8.51 40 5.97E-14
positive regulation of biological process 54.61 117 5.05E-13
extracellular region 69.92 137 1.52E-12
response to stimulus 96.89 169 1.95E-11
immune response 20.83 60 2.38E-11
positive regulation of cellular process 48.25 102 5.56E-11
cell proliferation 27.02 69 1.03E-10
positive regulation of immune system process 8.68 35 2.13E-10
protein binding 229.75 319 3.08E-10
regulation of cell proliferation 19.74 54 2.25E-09
response to external stimulus 25.05 62 4.78E-09
ensheathment of neurons 1.49 14 5.75E-09
axon ensheathment 1.49 14 5.75E-09
regulation of immune response 7.94 31 6.83E-09
positive regulation of response to stimulus 7.15 29 1.05E-08
positive regulation of immune response 5.83 26 1.08E-08
regulation of immune system process 12.90 40 1.72E-08
regulation of action potential in neuron 1.67 14 2.70E-08
myelination 1.40 13 2.70E-08
developmental process 126.76 192 4.64E-08
pattern binding 5.00 23 5.31E-08
polysaccharide binding 5.00 23 5.31E-08
response to stress 47.94 92 7.33E-08
regulation of response to stimulus 12.59 38 8.43E-08
cell adhesion 25.48 59 1.09E-07
biological adhesion 25.48 59 1.09E-07
defense response 19.83 50 1.14E-07
cell surface 10.66 34 1.33E-07
immune effector process 7.68 28 1.68E-07
inflammatory response 10.26 33 1.78E-07
lymphocyte mediated immunity 5.44 23 2.29E-07
regulation of action potential 2.02 14 3.08E-07
response to wounding 15.04 41 3.08E-07
carbohydrate binding 13.29 38 3.08E-07
leukocyte mediated immunity 6.01 24 3.14E-07
regulation of multicellular organismal process 30.09 64 4.90E-07
adaptive immune response 5.31 22 6.06E-07
adaptive immune response based on somatic recombination of immune receptors
built from immunoglobulin superfamily domains
5.31 22 6.06E-07
regulation of developmental process 39.43 77 6.06E-07
anatomical structure development 92.28 145 6.49E-07
chemical homeostasis 13.82 38 7.31E-07
external side of plasma membrane 7.37 26 9.12E-07
doi:10.1371/journal.pone.0032419.t003
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increases and decreases in expression of apoptotic genes, and for
both positive and negative regulators of apoptosis (Table S4) in
contrast to a qPCR study [33]. Taken together the data indicates
that the net biological effect of the dys-regulated genes in apoptotic
pathways was neutral.
There were no significant gene changes for PHF-Tau or alpha-
synuclein, consistent with the previous negative histopathology
findings [3]. However, there also were no changes detected in
neurofilament genes and relatively minor changes in genes
associated with ubiquitination, both of which are significantly
increased in specific brain regions by immunohistochemical
analysis [3]. In the immunohistochemical analysis the numbers
of Ubq/NFL+ cells were significantly increased in MPS VII but
were a relatively small proportion of each region, thus gene
expression changes within these cells would probably not be
distinguishable from background in the array analysis since whole
region homogenates were assayed.
Changes in expression of other genes that have been associated
with neurodegeneration include: 1) cerebellar degeneration-related
2 (Cdr2) which was down-regulated in the HP (although not in the
CB); 2) reduced expression in transcription factors associated with
neurogenetic diseases (e.g. Fos, JunB) was seen in the CB; and 3)
decreased expression of glycine amidinotransferase (Gatm) in the
BS, a gene associated with mental retardation [34]. Overall, the
data are consistent with histological studies in which neuronal loss is
not a major feature of lysosomal storage diseases [1].
4b. Astrogliosis. Astrogliosis is a feature of many neuro-
degenerative diseases [35], including the MPS VII mouse [3]. Of
the top 40 astrocyte cell-specific genes identified in vitro [32], 13
were changed, all of which were up-regulated (Table S5). Genes
associated with astrocytosis were up-regulated, including: GFAP,
which was up-regulated in all regions and confirmed by RT-PCR
(Fig. S1); vimentin, a part of the astrocyte intermediate filament
and a hallmark of reactive gliosis [36], in the CT, OB and ST; and
markers associated with cell metabolism (Aldoc), cell transport and
ion binding (Aqp4, Slc14a1), and signal transduction (Mertk). The
most specific marker gene for astrocytes in vitro [32], Aldh1L1,
was not changed in any region in the MPS VII brain. Likewise, a
number of markers associated with severe astrogliosis were not
changed [35,37]. These data are consistent with the histological
findings which show moderate astrogliosis [3].
4c. Microglia, immune system and inflammatory
changes. Many of the genes involved in activation of
microglia and immunity were among the most significantly up-
regulated of all the changed genes in the MPS VII mouse brain,
including 25 of the 36 most significant genes (average p* across
regions ,0.0001) (Figure 3). Some examples were: Gpnmb, a
negative regulator of proinflammatory response; Cd68; Fcgr2b,
the low affinity Fc receptor for IgG; Clec7a, a receptor which
recognizes some glucans from fungi and plants; Mpeg1, a
macrophage expressed gene; 3 complement components, C1qc,
C1qb, and C4b; Trem2 which may have a role in chronic
inflammation; lysozyme 1 and 2; Fcrls, the Fc receptor-like S, a
scavenger receptor; and, Hpgds, which plays a role in the
production of prostanoids in the immune system. Regional
differences were seen, with the largest number altered in the OB.
The DAVID analysis found 345 gene changes in 29 functional
categories (out of 253) involving the immune system or
inflammation (Table S1). These inflammatory categories were in
the top one-eighth of the overall list ranked by the strength of the
associations. Prominent categorical changes included up-regula-
tion of the cathepsin genes, the products of which are released by
activated microglia, have been implicated in the pro-inflammatory
response, and are associated with neuronal death and apoptosis.
The cathepsins Ctsa, Ctsb, Ctsc, Ctsd, Ctsh, Ctss and Ctsz were
highly up-regulated in all brain regions, while Ctsk was only
changed in the BS and was down-regulated. The toll-like receptors
(TLRs) play a role in innate immunity and TLRs 2, 3, 4 and 7
were up-regulated in some regions (Figure 4). There were also a
number of changes in the complement pathway.
However, many other genes that associated with a pro-
inflammatory response were notc h a n g e di nt h eM P SV I Ib r a i n s .
Interleukins are the primary cytokines seen in inflammation, but only
af e wo ft h e s ew e r ec h a n g e d( F i g u r e4 ) .T h eb i g g e s tc h a n g ew a si nt h e
interleukin-10receptorbeta,which wasup-regulated in 5regionsand
is involved in an anti-inflammatory pathway, but IL10 itself was
unchanged. The major pro-inflammatory cytokine, IL1b,w a sa l s o
unchanged while the IL1 receptor accessory gene (IL1rap), which is a
necessary part of the interleukin 1 receptor complex, was down-
regulated in two regions. The pleiotrophic IL6 was unchanged, but
Stat3, the anti-apoptotic effector of IL6, was up-regulated in the OB.
Chemokine changeswerealso largelyabsent withtheexception ofthe
up-regulation of Ccl3 and the down-regulation of Ccl12 in the OB
and the down-regulation of Ccl9 in the CT. Another important set of
pathways in inflammation involves the mitogen-activated protein
kinase (MAPK) cascades [38] but none of the Mapk genes were
altered. Additionally, the genes for the GO-term ‘‘Leukocyte
transendothelialmigration’’were under-represented inthe GeneTrail
analysis from our list of changed genes. Finally, several anti-
inflammatory molecules were highly up-regulated, including Ilt3/
Gp49a, FccrIIb, Tyrobp, Cd300a and Cd300lf.
4d. Circadian Rhythm. Alterations in circadian rhythm
have been documented in the MPS VII mouse [39], and 17 genes
known to be involved in circadian rhythm [40] were altered in the
MPS VII brain (Figure 5). Eight of these were found in the BS,
consistent with the biology of circadian rhythm. Urotensin II,
(Uts2), up-regulated in the BS is vasoactive and also has an effect
on cholinergic neurons involved in REM sleep [41,42,43].
Another vasoactive gene involved in circadian rhythm, arginine
vasopressin (Avp), was also up-regulated in the ST. In the
GeneTrail analysis the BS was the only one of the 6 regions that
generated GO term enrichment related to circadian rhythm and
regulation of heart rate.
5. Alterations in other neurological systems indicate the
presence of important additional pathological processes
In addition to the gene changes associated with previous
biochemical, histopathological and behavioral abnormalities,
Table 4. All KEGG pathways of significantly changed genes
(from Genetrail).
KEGG pathway expected observed p-value(fdr)
Lysosome 6.40 28 1.97E-09
Complement and coagulation cascade 3.97 13 8.67E-03
Cell adhesion molecules (CAMs) 6.40 28 3.43E-02
Huntington’s disease 3.97 13 3.43E-02
Other glycan degradation 8.78 19 3.43E-02
Adipocytokine signaling pathway 3.70 10 4.71E-02
Cytokine-cytokine receptor interaction 13.32 24 4.71E-02
Glycosaminoglycan degradation 1.06 5 4.71E-02
Pathways in cancer 18.29 31 4.71E-02
doi:10.1371/journal.pone.0032419.t004
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implicate other pathways of pathology.
5a. Gene changes associated with development. Ten
clusters of DAVID pathways were associated with nervous system
development terms and included: 1) 4 clusters related to stem cells
and other basic development terms such as regeneration,
mesenchymal cell and neural crest differentiation, pattern
formation, and homeobox genes (Figure 6); 2) 5 clusters related
to neuron development, such as neurogenesis, neuron fate
commitment, neuron projection development, axonogenesis, and
axon guidance (Figure 7); and 3) 1 cluster related to gliogenesis (see
section below on myelination).
Specific changes in the MPS VII brain included genes encoding
semiphorins, Trk receptors, BMPs, IGF-1, NGF, TGFß, and
receptors for FGF2 but not for EGF. Specific developmental genes
were increased or decreased across brain regions, but overall there
was no dominant pattern of up or down regulation (Figure 7).
Increased expression was seen in genes associated with neuronal
cell development and differentiation (e.g. Timp2, Adm, Ahnak,
Cxcr4, Igf1), growth of neurites or axons (Ntrk2), differentiation of
Figure 2. Changes in lysosome genes across regions in MPS VII brain. The key across the bottom shows the magnitude of significance
coded in shades of gray and the fold change and direction coded in shades of red for increased expression and shades of green for decreased
expression (the same key is used in figures 3–8). The values for each gene in each region are in the boxes. Gusb was down-regulated in all regions, as
expected, while other normal lysosomal genes were up-regulated consistent with enzymatic activity data.
doi:10.1371/journal.pone.0032419.g002
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Tgfbr2, Sepp1, B2m, Cebpa, Cebpd). Down-regulation in the
diseased brain was seen in genes associated with quantity of
neurites or axons (A2m) and with CNS development (e.g. BTG2,
Egr2, Sept4, Sema3b). The largest down-regulation was in the
Otx2 (orthodenticle homeobox 2) gene (8-fold with p*=10
23), but
only in the HP. This gene encodes a transcription factor
(homeobox 2) that controls neuron subtype identity, the fate of
GABAergic neurons, and forebrain development [29,30,31].
Many other developmental genes that were changed in the MPS
brain were associated with development of non-neuronal tissues.
For example, skeletal development clusters were seen in both the
DAVID and GeneTrail analyses of the brain tissue and skeletal
dys-genesis is a major feature of MPS diseases. MPS VII is a
disease with a distinct skeletal phenotype with thickened dense
bones similar to those seen in osteopetrosis. One of the most
significantly changed genes in the MPS VII brain was Gpnmb
(osteoactivin), which was originally cloned from an osteopetrosis
rat [44,45]. It is expressed in several areas of the normal adult
brain [15] and was very strongly up-regulated in all regions of the
MPS VII brain, yet the gene is not included in any of the DAVID
clusters for nervous system development. Osteopetrosis is also
associated with a decrease in Car2 (carbonic anhydrase 2), which
was down-regulated in 5 of 6 MPS VII brain regions. In addition
to Gpnmb and Car2, 23 other genes involved in skeleton and bone
development were altered in the diseased brain. Developmental
genes that were dys-regulated in the MPS VII brain were also
associated with development of blood vessels, the urogenital
system, endocrine pancreas, striated muscle, exocrine glands,
heart, reproductive organs, and retinal photoreceptors.
5b. Myelination. Many genes associated with oligoden-
drocytes were down-regulated even though MPS diseases as a
group are not classsified as leukodystrophies. Of the genes
identified as oligodendrocyte markers in vitro [32], 53% were
changed in the MPS VII brains and they were all down-regulated
(Figure 8). The reduced expression of Aspa, Mbp, Mobp, Plp1 and
Olig2 were confirmed by RT-PCR (Fig. S1). Interestingly, there
were changes in myelin associated genes in all regions except the
Figure 3. Genes most significantly altered in MPS VII brain. The genes are listed in order of decreasing average p* (step-up p value) across
regions. Only genes with p*,0.0001 are shown. The key is the same as in Fig. 2.
doi:10.1371/journal.pone.0032419.g003
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but not in the list of top marker genes identified in vitro [32], were
also altered in the MPS VII brains and most were down-regulated.
Ten of the 60 genes from the nervous system development
category (see above) are involved in myelination, of which 8 were
down-regulated. The 2 that were up-regulated, were only altered
in the OB: Ptprz1 (protein tyrosine phosphatase, receptor-type, Z
polypeptide 1) is expressed in the remyelinating oligodendrocytes
of multiple sclerosis lesions [46]; and Pmp22 (peripheral myelin
protein 22) is a component of myelin. Three additional myelin-
associated genes (by GO-term) were also up-regulated in the OB:
Cd9 (in the CT as well as OB) is associated with late events in
myelin maturation [47]; Lgi4 promotes the proliferation and
differentiation of glial lineage cells in the peripheral nervous
system [48]; and Tgfb1 is induced by activated microglia [49].
5c. Transport and ion channels. Eight functional clusters
in the DAVID analysis containing 137 altered genes were
associated with solute carriers and ion channels. Changes were
found in voltage gated proton, potassium, and chloride channels,
but not in sodium or calcium voltage gated channels. Only one
changed gene was associated with action potential (Kcnn2) and it
was only changed in the BS, which is consistent with the dearth of
neuron-associated changes (see above).
5d. Cell adhesion and extracellular matrix. The fourth
and seventh highest ranked DAVID functional clusters of genes
involved cell adhesion and binding to carbohydrates, polysac-
charides and glycosaminoglycans. Three gene changes were seen in
all brain regions: Gpnmb (see 4c above) which was highly up-
regulated; Clec7a, a C-type lectin, a microglia marker gene that
recognizes glucans, which was highly up-regulated [50]; and Selplg,
which was down-regulated and is the ligand for P-selectin [51].
5e. Signaling,cell cycle,nucleus, and gene regulation. The
DAVID analysis found 5 functional annotation clusters containing
210 genes that thematically grouped into 4 main categories: mapkkk,
Egf-like, nucleotide binding, and kinase-related activity. The OB had
the largest number of changes, including 3 times as many with
p*,10
27 as any other region. The total number of genes changed
a n dd e g r e eo fc h a n g ew a ss e c o n do n l yt ot h ei m m u n i t yc l u s t e r .
Nevertheless, when we examined all the changes in the context of the
pathways in which they occurred, none of them showed a crucial
junction point or a group of changes within one pathway that would
implicate a specific pathway as deficient.
5f. Metabolism. This broad based term involves many
different systems, both anabolic and catabolic. Alterations in 3
DAVID functional annotation clusters included 54 genes, with the
largest number of changes (30) found in the OB. Most of the
changed genes were up-regulated, with only 4 being down-
regulated (including Gusb). The top changes were in lysosomal
enzyme genes, which are included in this category due to their
catabolic function. One interesting change was Aldoc, a glycolytic
enzyme that was highly up-regulated (p*=10
211) in all regions
except the CB. Aldoc is directly inducible by hypoxia inducing
factor 1a [52], which was down-regulated in the CB. Another
change limited to the CB was in klotho (Kl), which had the largest
fold change in the metabolism genes with an 8-fold over-
expression. Klotho is a novel b-glucuronidase potentially capable
Figure 4. Changes in genes associated with immune system
and inflammation. The genes are grouped by class (as used in
DiRosario et al., 2009) and then sorted by fold within class. Genes
highlighted in yellow were changed in both MPS VII and MPS IIIb
[58,60]. Genes listed at the bottom were changed in MPS IIIb but not in
MPS VII. Key as in Fig. 2.
doi:10.1371/journal.pone.0032419.g004
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Fa2h (fatty acid 2-hydroxylase) was down-regulated in the CT, HP
and OB. Mutations in the Fa2h gene are associated with leuko-
dystrophic dys-myelination and other brain neurodegeneration [54].
5g. Olfactory bulb neuronal changes. Changes specifically
attributable to neurons were observed in the OB. Olfactory marker
protein (OMP), a gene that is expressed almost exclusively on
mature primary olfactory sensory neurons [55], was highly down-
regulated (11-fold with p*,10
213). Mice that lack OMP have
perturbed electrophysiological activity and altered spatio-
temporal activity patterns for different odorants [28,56]. No
changes in the olfactory neuronal receptor genes were found
suggesting that neuronal loss is not responsible for the OMP
decrease. Changes in human olfaction have been shown and often
precede diagnosis in a number of immune/inflammatory associated
brain diseases such as MS, Alzheimer and Parkinson’s disease [57].
Discussion
Assaying the brain in separate anatomic structures, and using a
large cohort of mice for robust power, allowed detection of a large
number of specific, highly significant changes in gene expression.
The changes shared by multiple regions were mostly attributable
to generalized cellular functions (e.g. lysosomal genes) or
widespread pathology (e.g. activated microglial genes). However,
most changes occurred in only one region, reflecting regional gene
specialization, and specific categories of genes varied in number
and direction-of-change by region. For example, the OB had the
largest number of altered genes, which included some of the most
highly changed genes in any region (e.g. OMP, important
functions in olfaction). Additionally, the OB had more changes
indicative of inflammation than other areas. For oligodendrocyte
and myelination genes, the hippocampus had the most changes,
whereas the cerebellum had only one, which parallels the
magnitude and direction of changes in storage [9].
Some systems were changed primarily in one direction, e.g.
most oligodendrocyte genes were down-regulated and most
lysosomal genes were up-regulated, while other systems were
mixed, e.g. apoptosis. Several of the changed pathways were
concordant with known alterations in lysosomal, immunological,
astroglial, neurodegenerative, and metabolic systems. Additionally,
however, the power and regional analysis were sensitive enough to
detect changes in systems involved in neurological dysfunction but
which have not been previously appreciated in MPS brains,
indicating they are contributing to the overall pathological milieu
that results in brain disease.
Immune and inflammatory system
One of the most interesting categories involved the immune/
inflammation system, a general aspect of MPS disorders and
neurodegenerative diseases [8,58,59], There were notable differ-
ences between MPS VII and the closely related MPS IIIb which is
the best-studied MPS mouse model for gene expression in the
brain [58,60,61,62]. Some of the most highly up-regulated genes
in MPS VII were associated with activation of microglia (e.g.
Cd68, Mpeg1), as in MPS IIIb, but the MPS VII brain had a
notable absence of changes in most genes associated with
inflammation, which are significantly changed in MPS IIIb. The
few changes in inflammatory genes in MPS VII occurred mostly in
the OB. Additionally, lower amounts of A-beta have been found in
MPS VII versus MPS IIIb [63]. Consistent with this, MPS IIIb
accumulates PHF-Tau in a select region of the cerebral cortex
[64], but is not altered in the MPS VII brain [3].
Dissimilar signaling from the predominant, undegraded GAG
of each disease may drive the differences in immune and
inflammatory phenotypes between MPS VII and MPS IIIb.
Substrate specificity of each mutated enzyme results in accumu-
lation of only heparan sulfate (HS) in MPS IIIb whereas MPS VII
cells primarily accumulate chondroitin sulfates (CS), with lesser
amounts of HS and dermatan sulfate (DS) [8,65]. In MPS I mice
(a model of Hurler disease caused by alpha-L-iduronidase
deficiency) both HS and DS accumulate and the mice have
similar changes in microglial activation genes as MPS IIIb;
however, genes associated with inflammation are not up-regulated
Figure 5. Changes in genes associated with circadian rhythm. The GeneTrail analysis found the GO term circadian rhythm to only be
associated with the brainstem. Key as in Fig. 2.
doi:10.1371/journal.pone.0032419.g005
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inflammatory and immune gene pathways may be similar to CS,
consistent with their closely related structures [66]. These
differences may have functional significance because human
Sanfilippo disease patients have severe intellectual impairment
whereas Sly disease patients are much more variable with some
having near normal intelligence [8].
The differences are consistent with known effects of HS and CS
on inflammation and the immune system in non-LSD brains
[67,68]. HS stimulates dendritic cells through Tlr4 in MPS IIIb
[61] whereas CS has immunomodulatory and anti-inflammatory
effects [69,70,71]. Also CS disaccharide can induce microglia to
adopt a regulatory phenotype that is anti-inflammatory, IFN-
gamma counter-regulatory, and neuroprotective [69,70].
A candidate gene for mediating the diminished inflammatory
phenotype of MPS VII is Gpnmb, which was the most significantly
up-regulated of all gene changes in MPS VII yet was not altered in
MPS I or MPS IIIb. Gpnmb is expressed on antigen presenting
cells [72] and blocks the production of inflammatory cytokines
[73]. Other anti-inflammatory genes were also highly up-regulated
in the MPS VII brain (e.g. Ilt3/Gp49a, FccrIIb, Tyrobp, Cd300a,
Cd300lf, Il10rb). Concordantly, a number of inflammatory-
associated genes such as cytokines, chemokines and Cd genes
were down-regulated.
Myelination
The strong down-regulation of oligodendrocyte genes involved
in myelination was unexpected since white matter involvement is
not seen by histopathology [9]. However, this may be explained by
the strong association between neuroinflammation and dysmyeli-
nating diseases in general [59]. Although white matter changes are
not observed histopathologically in MPS VII, we recently found
that a reduction in white matter can be detected by high-
resolution, ex vivo MRI analysis [74]. Thus, the changes in
oligodendrocyte genes appear to correlate with mild dysmyelina-
tion. This may have a functional consequence because the gene
changes that were identified by the GO term ‘‘regulation of action
potential’’ are linked to oligodendrocytes rather than neurons.
Neurodegeneration
Children with MPS VII show varying amounts of mental
retardation [8], but there were no changes in the neuronal marker
genes [32]. Moreover, of 159 probes for 8 classes of neuron
receptors, only four changes were found, all in different regions
and all with low significance. In contrast, neurodegeneration
lesions are found in the HP, ST and CT of MPS VII mice [3].
They are characterized by excess ubiquitin and neurofiliment
accumulation and up-regulation of the ubiquitin specific peptidase
53 (Usp53) gene was detected in the HP, OB, BS and ST. The
ubiquitin-proteosome system (UPS) is implicated in the pathogen-
esis of several neurodegenerative disorders [75] and is also
important in neuroprotection [76].
Developmental pathways
Many changes were seen in genes associated with neural
development and differentiation. However, no specific pathway or
subset of developmental processes was implicated, suggesting a
more diffuse effect resulting in activation of different gene sets in
different cell types. The major elements of brain anatomical
patterning are maintained in the MPS VII brain and there is no
Figure 6. Changes in genes associated with embryonic development and stem cells. Key as in Fig. 2.
doi:10.1371/journal.pone.0032419.g006
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doi:10.1371/journal.pone.0032419.g007
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phenotype [3]. Thus the activation of developmental genes may be
triggered by the diseased microenvironment. CS affects several
aspects of nervous system development directly [77]. In addition,
the CS-rich microenvironment of the diseased brain affects
differentiation of neural stem cells in the MPS VII dog [78].
The changes in developmental genes may also be from reactive
astrocytes, which exhibit NSC characteristics [79] as MPS VII
mice have diffuse astrogliosis [3]. Two major markers of reactive
astrocytes were up-regulated: Gfap in all regions and vimentin
(Vim) in CT, OB, and ST.
A substantial number of the altered developmental and
differentiation genes are associated with non-CNS tissues, many
with the skeletal system. During embryogenesis the neural crest is
associated with development of both the nervous and skeletal
systems [80,81], suggesting that fundamental developmental
programs may be reactivated under the disease conditions.
Summary
The robust power of this study revealed a large number of gene
expression changes and variability by major brain subregion.
Some of the differences between the normal and MPS VII brains
were concordant with known histopathological, biochemical, and
behavioral abnormalities in the MPS VII mouse; but, a number of
altered systems have not been implicated previously and provide
fruitful directions for further investigation. The central role of CS
in signaling processes, cell-cell interactions, maintenance of the
extracellular space, and development [77] may account for many
of the gene alterations secondary to the primary monogenic
mutation. The differences in patterns of expression between the
immune and inflammatory system genes in MPS VII compared to
MPS IIIb appear to directly reflect the predominant GAG
accumulated in each mutation. The decrease in expression of
major oligodendrocyte genes indicates defects in myelination. The
perturbations in developmental genes, while not implicating any
Figure 8. Oligodendrocyte gene changes in the MPS VII brain. The changes were all in the down-regulation direction suggesting
dysmyelination. Note the paucity of changes in the cerebellum. Key as in Fig. 2.
doi:10.1371/journal.pone.0032419.g008
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mental potential of neural progenitor cells due to the microenvi-
ronment, which would be expected to be pleiotropic. The large
number of gene changes in the OB and the availability of gene
vector and neural stem cell reagents for manipulating the OB in
the MPS VII model [82,83], indicate that olfaction may be useful
for probing the mechanisms of CS accumulation on a sensory
perception system in the brain.
These data also provide a basis to investigate the differences
between changes in gene expression and their manifestation as
protein changes and effects on cell function. Although further
understanding of the pathological effects will require specific
experiments targeted to the biochemistry and physiology of each
pathway, understanding which changes lead to specific patholog-
ical effects should result in a better understanding of the relative
contributions of the myriad altered sub-systems to overall
neuropathology. Furthermore, better understanding of the multi-
tude of effects in the diseased brain will provide more specific
parameters to evaluate the effect of therapies.
Materials and Methods
Ethics statement
All animal procedures were performed according to protocols
approved by the IACUC (Institutional Animal Care and Use
Committee) of the Children’s Hospital of Philadelphia (CHOP).
Online Data Repository
The primary microarray data for this paper is available at http://
www.ncbi.nlm.nih.gov/geo/ accession number GSE34071.
MPS VII animal model
Wild-type (gus
+/gus
+), carriers (gus
mps/gus
+) and MPS VII-
affected (gus
mps/gus
mps) on the C3H-HeOuJ background [84] were
maintained in our breeding colony through carrier-carrier
brother-sister mating. Identification of the MPS VII-affected mice,
which contain a single base pair deletion in exon 10 of the GUSB
gene, was verified by PCR genotyping, as described previously
[85]. Diseased and normal mice were housed together until brain
harvest at 5 months of age. Four litters were used that were born
within one week of each other and each litter contained at least
one mutant and one normal (genotypic carrier or wild-type) pup.
The group included 3 genotypic normal (Wt), 5 carrier (C) and 8
MPS VII (M) mice. To obtain a sufficient number of paired
animals for the study, it was necessary to use a mixture of genders
for both the normal control group (2 female, 6 male) and MPS VII
group (4 female, 4 male). Thus the gene expression data from
males and female were considered as one group of normal (Wt/C)
or MPS VII (M) brains.
Micro-dissection of brains
At 21–22 weeks of age mice were anesthetized with ketamine/
xylazine and the brains were removed and placed immediately on
ice. The hemispheres were separated along the medial longitudinal
fissure and each hemisphere was further dissected based on
anatomical boundaries to obtain the following brain regions:
cerebellum (CB), brainstem (BS), olfactory bulb (OB), cerebral
cortex (CT), hippocampus (HP), and the remaining mid and
forebrain portion which included the striatum and thalamus (ST).
The brain pieces were immediately frozen in liquid nitrogen and
stored at 280Cu until used for RNA isolation.
RNA isolation
Total RNA was isolated separately from each of the six regions
of the right hemisphere. Frozen regions were placed into TRIzol
(Invitrogen) at 1 ml per sample and homogenized (Pellet Pestle
Motor - Kontes, VWR) at maximum speed for 20–40 Sec. The
RNA was further purified using the RNeasy Lipid Tissue mini kit
(Qiagen) according to manufacturer’s instructions. Total RNA
quality was assessed by measuring the A260/280 ratio on a
NanoDrop ND-1000 spectrophotometer (Thermo Scientific).
RNA integrity was verified by visualization of the 28S and 18S
ribosomal rRNA bands, with no presence of smear, using a
denaturing TAE- agarose gel.
Microarrays
1 mg RNA from each brain region was used to prepare
biotinylated aRNA samples using the MessageAMP II-biotin
Enhanced Signal Round aRNA Amplification Kit (Ambion).
Reverse transcription, in vitro transcription and fragmentation
were performed according to manufacturer’s instructions (Am-
bion). Samples of 10 mg aRNA were hybridized on Affymetrix
mouse genome 430A 2.0 Gene Chips containing 22,690
oligonucleotide probe sets (www.affymetrix.com). A total of 96
samples (16 brains, 6 regions each) were hybridized. Hybridiza-
tion, staining and washing were performed on an Affymetrix
Fluidics Station 400 at the Children’s Hospital of Philadelphia
Nucleic Acid Core facility according to Affymetrix protocols.
Scanning was performed using the Affymetrix Gene Chip Scanner
3000 controlled by a GeneChip Operating software 1.4 (GCOS,
Affymetrix).
Data normalization and analysis
Raw microarray image files were processed using the Affymetrix
GCOS 1.4 software to calculate individual probe cell intensity
data and generate CEL data files. The 96 Affymetrix CEL files
were imported into Partek Genomics Suite (v6.5, Partek Inc. St.
Louis, MO) where GCRMA was applied. Clustering approaches
and principle components analysis showed two of the arrays were
outliers, which were excluded for subsequent statistical analysis.
For the remaining 94 arrays, a 3-way mixed model ANOVA
was calculated including the factors genotype (2 levels with wild-
type and carrier combined as ‘‘normal’’ as described above),
region (6 levels), and mouse ID (16 levels). An interaction term
between genotype and region was included as well. In conjunction
with the ANOVA, we calculated pairwise contrasts (each yielding
a p-value and a fold change) for genotype for each of the 6 brain
regions. For all resulting p-values, a corrected step-up p-value (p*)
(False Discovery Rate by the Benjamini Hochberg step-up method
as implemented in Partek) was calculated. A p*#0.01 without
prejudice for fold change was used to select the genes differentially
expressed in MPS VII mice.
For regional gene enrichment in the normal mouse, a two way
mixed model ANOVA was calculated using the factors region
(6 levels) and mouse ID (8 levels). p* was calculated as above.
Regional gene enrichment fold in the normal brain was calculated
by dividing the regional average by the average of all the
remaining regions.
Functional analysis of the data sets
The significantly changed (p,0.01) genes were analyzed using
GeneTrail (http://genetrail.bioinf.uni-sb.de/) [17] for Gene
Ontology (GO) term [18] and KEGG [19] pathway enrichment,
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other database functional clustering, or from literature-search
generated gene lists as described in the results section. Hierarchical
clustering of the differentially expressed genes and heatmap
generation was carried out using the MultiExperiment Viewer
(MeV) tool in TM4 Microarray Software suite (http://www.tm4.
org/mev.html) [86].
Quantitative RT (reverse transcriptase)-PCR and data
analysis
To validate the microarray data, nine differentially expressed
genes were chosen for quantitative real time PCR analysis (Q-
PCR) using the following TaqMan gene expression assays:
beta-glucuronidase (Gusb, Mm03003537_s1); hexosaminidase B
(Hexb, Mm00599880_m1); glial fibrillary acidic protein (Gfap,
Mm00546086_m1); lysozyme (Lyz2, Mm00727183_s1), myelin-
associated oligodendrocytic basic protein (Mobp, Mm0048-
5088_m1), myelin basic protein (Mbp, Mm01262035_m1),
proteolipid protein (myelin) 1 (Plp, Mm00456892_m1), oligoden-
drocyte transcription factor 2 (Olig2, Mm01210556_m1), and
aspartoacylase (aminoacylase) 2 (Aspa, Mm00480867_m1). The
18 s ribosomal subunit (18 s rRNA, Hs 99999901_s1) was used as
a reference gene.
The same RNA samples used in the microarray analysis were
also used for Q-PCR. The total RNA samples treated with DNase
(turbo DNA free, Ambion) and then reverse transcribed using a
high capacity cDNA reverse transcription kit (Applied Biosystems)
and then amplified. The changes in reporter fluorescence were
monitored using the ABI SDS 7500 system (Applied Biosystems)
run with the standard program. The data is expressed as mean fold
changes in the MPS VII compared to the normals. Similar results
in both the direction and the magnitude of change were achieved
by both assay methods (Fig. S1).
Rationale for grouping wild-type and carriers together
The disease requires inheritance of homozygous mutant alleles
and there is no evidence of disease in heterozygous carriers in mice
or humans. An initial analysis on HP samples using hierarchical
clustering of the expression values of the 50 top and bottom
significantly altered genes by fold change (p,0.01) between Wt, C
and M mice, clustered the wild-type and carrier mice together and
distinct from the mutants (Fig. S2). Also, the larger microarray
dataset was compared using a principal component analysis (PCA)
derived from an ANOVA, which compared genotype, region, and
the interaction between the them for the most significant 500
probes, which showed that the wild-type and carrier samples
segregated together and the mutants segregated separately
(Fig. S3). This genotypic analysis is consistent with the known
phenotype in which carriers and normals are indistinguishable
[21,84]. Thus for analysis, we grouped the genotypically
homozygous wild-type (Wt) and heterozygous carrier (C) samples
together in a group that has a normal phenotype (N).
Data presentation for figures
When multiple probes are present for the same gene, the probe
data with less significance has been eliminated for brevity. If the
eliminated probe showed statistically significant regional informa-
tion not found in the non-eliminated probe data, the data was
consolidated for the purpose of presentation.
Supporting Information
Figure S1 Comparison of fold change by RT-PCR and
microarray for selected genes.
(TIF)
Figure S2 Heatmap showing that the normal and
carrier groups are similar to each other and distinct
from the mutants. The top and bottom 50 hippocampal genes
are displayed; the values are the difference from the mean.
(TIF)
Figure S3 Plot of Primary Component Analysis (PCA) by
genotype and region showing that carriers and wild-type
samples segregate from mutants.
(TIF)
Table S1 Thematic consolidation of DAVID annotation
clusters.
(XLS)
Table S2 Gene expression altered or unaltered exclu-
sively in one region (orange=upregulated/green=
downregulated).
(XLS)
Table S3 Neuronal receptor changes.
(XLS)
Table S4 Gene expression changes associated with the
GO terms Positive regulation of apoptosis and Negative
regulation of apoptosis (orange=upregulated/green=
downregulated).
(XLS)
Table S5 Changes in astrocyte marker genes.
(XLS)
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